Lifetime Treatment Burden of Patients With Mantle Cell Lymphoma: Simulation‐based Analysis of Real‐world Data From 20 Years

Abstract

SUPPLEMENT ABSTRACTS 85 (15.5 %). A total of 362 (66.1%) of patients had died from MCL and 166 (30.3%) from other causes. The median number of treatment lines received both at 10 and 20 years of follow-up was three. Conclusions:In this study, we estimated the number of treatment lines patients with MCL receive during a 20-year follow-up. The estimation we provide serves as a tool to determine the number of MCL patients that could potentially receive novel therapies during each stage of follow-up. This would contribute to the accuracy of evaluation of health economical costs, thus, allocation of the new, expensive cancer treatments.